Body mass index and aromatase inhibitors: a step forward in individualizing therapy for breast cancer patients?
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Body mass index and aromatase inhibitors: a step forward in individualizing therapy for breast cancer patients?
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 16, Issue 7, Pages 759-766
Publisher
Informa UK Limited
Online
2016-05-20
DOI
10.1080/14737140.2016.1191949
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer
- (2015) Lorenzo Rossi et al. Breast Care
- Role of RUNX2 in Breast Carcinogenesis
- (2015) Daniel Wysokinski et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Better Together: Targeted Combination Therapies in Breast Cancer
- (2015) Elisa Zanardi et al. SEMINARS IN ONCOLOGY
- Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole
- (2014) V Sini et al. BRITISH JOURNAL OF CANCER
- Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer
- (2014) K. M. Elliott et al. BRITISH JOURNAL OF SURGERY
- Does Obesity Interfere With Anastrozole Treatment? Positive Association Between Body Mass Index and Anastrozole Plasma Levels
- (2014) Michael Hubalek et al. Clinical Breast Cancer
- Obesity and endocrine therapy: Host factors and breast cancer outcome
- (2013) Pamela J. Goodwin BREAST
- Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer
- (2013) G Pfeiler et al. BRITISH JOURNAL OF CANCER
- Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
- (2013) G Pfeiler et al. BRITISH JOURNAL OF CANCER
- The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
- (2013) M Gnant et al. BRITISH JOURNAL OF CANCER
- Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole
- (2013) I. Kyvernitakis et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels
- (2012) Caroline Diorio et al. BREAST CANCER RESEARCH AND TREATMENT
- Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index
- (2012) M A N Sendur et al. BRITISH JOURNAL OF CANCER
- Abstract 3071: Obesity-associated growth factor signaling upregulates aromatase expression and estrogen receptor activity in breast cancer cells
- (2012) Laura W. Bowers et al. CANCER RESEARCH
- The pharmacokinetics of letrozole its association with key body mass metrics
- (2012) Seok-Joon Jin et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Aromatase Inhibition in Obese Women: How Much Is Enough?
- (2012) Jennifer A. Ligibel et al. JOURNAL OF CLINICAL ONCOLOGY
- Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial
- (2012) Marianne Ewertz et al. JOURNAL OF CLINICAL ONCOLOGY
- Suppression of Plasma Estrogen Levels by Letrozole and Anastrozole Is Related to Body Mass Index in Patients With Breast Cancer
- (2012) Elizabeth J. Folkerd et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer
- (2011) Masahiro Takada et al. BREAST
- Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle
- (2011) R. Wolters et al. BREAST CANCER RESEARCH AND TREATMENT
- Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age
- (2011) Z Desta et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial
- (2011) Georg Pfeiler et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis
- (2010) Melinda Protani et al. BREAST CANCER RESEARCH AND TREATMENT
- Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
- (2010) Ivana Sestak et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications
- (2010) Antonio Macciò et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Accuracy of body mass index in diagnosing obesity in the adult general population
- (2008) A Romero-Corral et al. INTERNATIONAL JOURNAL OF OBESITY
- Karyotype Evolution on Fluorescent In Situ Hybridization Analysis Is Associated With Short Survival in Patients With Chronic Lymphocytic Leukemia and Is Related to CD49d Expression
- (2008) Tait D. Shanafelt et al. JOURNAL OF CLINICAL ONCOLOGY
- Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women
- (2008) M. J. Gunter et al. JNCI-Journal of the National Cancer Institute
- Adipose-derived stem cells: Isolation, expansion and differentiation☆
- (2008) B BUNNELL et al. METHODS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More